Healthcare Insights by KYBORA

Our Founder & CEO, Alan Vanderborght, talks with veteran biotech CFO and Chairman of the Board at Egetis Therapeutics, Mats Blom, about a finance-first career across Europe and the US, what AI could mean for drug development, and the personal pull of rare disease - where success is measured in the handful of faces you can actually see.

In this episode, our Founder & CEO, Alan Vanderborght, sits down with Carter King, EVP Business Development at Protagonist Therapeutics, for a candid conversation about his journey to the frontier of drug development, the science of turning injectables therapies into pills, and the deal-making wisdom and resilience behind a 25-year carreer in biotech.

In this episode, our Founder & CEO, Alan Vanderborght, sits down with Celia Beline, CEO of Cilcare, for a conversation about pioneering the field of hearing health, the strategic development of disease-modifying drugs for "hidden" hearing loss, and the critical discovery that hearing is a primary modifiable risk factor for dementia. 

In this episode, Alan sits down with Nicolas Coudurier, CEO of Biocodex, for a conversation on leading a family-owned global giant, the strategic integration of AI, the evolution of microbiome science and its connection to the brain. Nicolas shares insights from his career journey, including what it takes to drive continuous change while successfully scaling across several subsidiaries.

In this episode, Alan sits down with David H. Crean,Chief Business Officer at MediciNova, for a conversation on leadership,strategy, and navigating complexity in the biopharma industry. David shares insights from his career journey and whatit takes to build value in late-stage biotech. They explore decision-making inhigh-risk environments, the role of strategic partnerships, and the challengesof a...

In this episode of Healthcare Insights by KYBORA, our CEO & Founder, Alan Vanderborght, sits down with David Apelian, CEO at Theolytics, for a conversation about the industry. Together, they explore immunotherapy, AI, and the innerworkings of clinical trials.

In this episode, our CEO Alan Vanderborght sits down with William Compton, SVP, Digital Enabling Functions and Colleague Services at Pfizer. Together, they discuss the effects of AI on the industry and what the future may look like.

In this episode, KYBORA's CEO, Alan Vanderborght, sits down with Richard Davies, Deputy Chairman of the Board at Alvotech, for a conversation about Richard's extensive industry experience, the current state of Biopharma, funding hurdles and the future of the industry.

KYBORA's CEO, Alan Vanderborght, sits down with Raya Therapeutic Founder, Anjan Aralihalli, for an inspiring conversation about Anjan's background, ALS breakthroughs and how Raya Therapeutic came to be.

Join us for our third episode! KYBORA's CEO Alan Vanderborght invites Dr. Weiyong Sun, Chief Business Officer at Hansoh Bio, for an insightful conversation about current issues in the industry, including the impact of China's growing R&D capabilities on the US pharmaceutical business.

In this episode, KYBORA's CEO Alan Vanderborght, and guest Carlo De Notaristefani, President at CDN Advising, discuss supply chain management, tariff pressures and the evolution of the Biopharma industry.

In the first episode of our podcast, guest John Gregg and host Alan Vanderborght discuss John's time and extensive experience in the industry, as well as various scientific innovations and the future of the healthcare industry.